Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 29, 2021
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Journal: Clinical genitourinary cancer
Published: January 17, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Journal: Clinical genitourinary cancer
Published: January 17, 2020
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Journal: Drug design, development and therapy
Published: September 19, 2017
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
Journal: Cancer management and research
Published: June 06, 2017
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: April 04, 2016
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Journal: Future oncology (London, England)
Published: March 22, 2016
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Journal: Cancer
Published: January 20, 2016
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 21, 2015
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.
Journal: Leukemia research
Published: October 21, 2015
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Journal: Clinical colorectal cancer
Published: October 02, 2015
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Journal: The Lancet. Oncology
Published: March 11, 2015
Last Updated: 09/26/2026